Pan Z, Yang B, Liu Y
Liver Cancer Institute, Zhongshan Hospital, Shanghai Medical University.
Zhonghua Yi Xue Za Zhi. 1998 Aug;78(8):595-7.
To detect the expression of three TGF beta isoforms and its clinicopathologic significance in hepatocellular carcinoma(HCC).
Surgical specimens of 52 patients with small HCC resection during 1992-1995 were used to determine the immunoreactivity of TGF beta protein by ABC immunohistochemistry. These specimens were divided into recurrence group(G1) and recurrence group(G2) according to whether HCC recurred two years after resection. The relations with recurrence of HCC were analyzed.
The positive rates in G1 and G2 were 85% (17/20) versus 47% (15/32) for TGF beta 1, 90% (18/20) vs. 78% (25/32) for TGF beta 2, and 45% (9/20) vs. 63% (20/32) for TGF beta 3. Significant difference was found in TGF beta 1 and TGF beta 2, but not in TGF beta 3.
The high immunoreactivity to TGF beta 1 or TGF beta 2 is positively related to the recurrence of HCC.
检测三种转化生长因子β（TGFβ）亚型在肝细胞癌（HCC）中的表达及其临床病理意义。
采用1992年至1995年间52例行小肝癌切除术患者的手术标本，通过ABC免疫组织化学法检测TGFβ蛋白的免疫反应性。根据肝癌切除术后两年内是否复发，将这些标本分为复发组（G1）和未复发组（G2）。分析其与肝癌复发的关系。
TGFβ1在G1组和G2组中的阳性率分别为85%（17/20）和47%（15/32），TGFβ2分别为90%（18/20）和78%（25/32），TGFβ3分别为45%（9/20）和63%（20/32）。TGFβ1和TGFβ2存在显著差异，而TGFβ3无显著差异。
对TGFβ1或TGFβ2的高免疫反应性与肝癌复发呈正相关。
